Course objectives:
๐ Define Large Language Models (LLMs)
๐ Describe LLM Use Cases
๐ Explain Prompt Tuning
๐ Describe Googleโs Gen AI Development tools #AI#ArtificialIntelligence#courses 2/3
It only takes an hour to get the fundamental concepts! ๐. Afterward, check out an insightful presentation from OpenAI, a competitor of Google, on the training and application of LLMs. #AI#ArtificialIntelligence#ChatGPT 3/3 ๐ง ๐
1/ "Fits at Chess" might seem like a punchline, but it's a real health concern ๐ง . I've been exploring research papers on the negative effects of #Chess on well-being, societies, and ecosystems, and found the first report of chess triggering #epilepsy from 1965. #NorwayChess
2/ These cases fall into a category of reflex #epilepsy - seizures are activated by specific, identifiable triggers. Such triggers can be external (flashing lights, hot water ๐ฟ), internal (emotions, thought ๐ญ), or a mix of both. #chess#NorwayChess#neuroscience#brain
3/ Among reflex #epilepsies, the most common are those triggered by visual stimuli or light changes (1 in 4,000). Much rarer triggers include eating ๐, music ๐ต(1:10 M), writing โ๏ธ, orgasm ๐ and even lying. #Chess, other #boardgames, and #cards can also trigger seizures.
1/4 Here we go! Chess eats your ๐ง gray matter!
"Grey matter volume and cortical thickness were reduced in chess players compared with those of control men in the occipitotemporal junction and precunei." #Chess#chesspunks#NorwayChess
2/4 Chess is a silent "killer" of ๐ง cortex locally.
๐กWho holds the record for the thinnest ๐ง cortex among chess players in history? Will collective chess ๐ง solve this mystery despite the thinning? Retweet! ๐ #Chess#chesspunks#brain#neuroscience#NorwayChess
3/4 ๐งฉ Stay tuned for more revelations from a treasure trove of almost 1000 scientific papers exploring the mental and other challenges of chess players. As a chess player myself, I hope for 1 or 2 papers highlighting the benefits of the game. #Chess#chesspunks#NorwayChess ๐
๐ Older adults make up 56% of the global cancer population, yet they're just 40% of participants in new cancer therapy trials. The underrepresentation of this key demographic in clinical trials is a major concern. #clinicaltrials#healthcare#aging
๐Trials biased towards younger patients without comorbidities and multiple prescription drugs yield cleaner datasets but may not provide sufficient evidence on drug safety and efficacy for older populations. 2/3 #ClinicalTrials#aging#healthcare
๐ US and UK regulators recognize the problem and have issued guidelines to address it recently. While guidelines and incentives can make a difference, legislation may be necessary to fully tackle the problem in the end. โ๏ธ 3/3 #ClinicalTrials#aging#healthcare#FDA